Clinical Commander

Back to dossier
cardio.cardiogenic-shock.post-stem-cell-transplant.v1PRODUCTION
cardio.cardiogenic-shock.post-stem-cell-transplant.v1

Cardiogenic shock — post-hematopoietic-stem-cell-transplant recipient

cardiologyacuteadult
Hard-required inputs
0 / 15
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm post-HSCT context; establish day-post-transplant + conditioning regimen + GVHD prophylaxis; identify suspected sub-etiology (cyclophosphamide hemorrhagic myocarditis vs CMV myocarditis vs sepsis-induced vs GVHD cardiac vs busulfan / TBI late effect)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Post-HSCT context established + sub-etiology hypothesis stated

Patient inputs (17)

Quantitative CMV viral load — peak 30-100 d post-allogeneic HSCT; PCR positive + cardiac dysfunction → CMV myocarditis differential

Older HSCT recipients higher cardiotoxicity risk; age informs prognosis and recovery candidacy

Allogeneic vs autologous; day-post-transplant determines etiology spectrum (early = conditioning toxicity; 30-100 d = CMV / GVHD)

Cyclophosphamide ≥120 mg/kg cumulative; busulfan; TBI dose — drives cardiotoxicity differential

Calcineurin inhibitor (cyclosporine / tacrolimus) on board → AKI risk + drug-interaction risk; informs avoid-list

Tachycardia common in sepsis-induced or volume-loss states; bradyarrhythmia in advanced cardiac toxicity

Baseline AKI; calcineurin inhibitor nephrotoxicity contributes; gadolinium contrast safety for CMR

Markedly elevated typical for cyclophosphamide hemorrhagic myocarditis or CMV myocarditis; trend correlates with severity

Acute HF marker; trend tracks recovery

Engraftment status; absolute neutrophil count gates infection-risk stratification + G-CSF decision

Sepsis-precipitated CS in immunosuppressed recipient; bacterial / fungal coverage decision

Biventricular function; pericardial effusion (cyclophosphamide hemorrhagic pericarditis); regional vs global pattern

Diffuse ST/T-wave changes; PR depression in pericarditis overlap; new conduction abnormality possible in myocarditis

SCAI 2022 staging baseline; gates vasopressor escalation

SCAI 2022 staging + CardShock prognostication (Harjola EHJ 2015 PMID 26333869)

Lake Louise Criteria 2018 (Ferreira PMID 30025572); T2*/SWI hemorrhagic signal in cyclophosphamide myocarditis; deferred until stable for transport + adequate eGFR for gadolinium

Reserved for diagnosis-changing scenarios — viral PCR negative + atypical pattern; per AHA/ACC/ESC 2007 EMB consensus (Cooper PMID 17998456)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningcyclophosphamide_hemorrhagic_myocarditis_with_refractory_shock
    Refractory CS within 1–10 d of high-dose cyclophosphamide (≥120 mg/kg) conditioning with hemorrhagic CMR pattern (T2*/SWI signal) — high-mortality variant (Goldberg JCO 1986); demands pulse steroids + supportive + MCS bridge with MDT
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcmv_myocarditis_pcr_confirmed_with_cardiac_dysfunction
    CMV PCR positive (whole blood) + cardiac dysfunction in post-allogeneic HSCT recipient (peak 30–100 d post-transplant) — emergent ganciclovir + IVIG + ID consult; consider EMB
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsepsis_precipitated_cs_in_neutropenic_post_hsct
    Sepsis physiology + cardiac dysfunction in profoundly neutropenic post-HSCT recipient (ANC <500) — mortality very high; SSC 2026 sepsis bundle + broad-spectrum + antifungal + G-CSF + early MCS evaluation with MDT
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningventricular_electrical_storm_in_post_hsct_inflamed_myocardium
    Sustained VT/VF or recurrent shocks within 24 h in post-HSCT recipient — high arrhythmia risk in inflamed myocardium; amiodarone + EP + escalate to MCS over higher inotropes; consider catheter ablation if refractory
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveregvhd_cardiac_involvement_with_hemodynamic_compromise
    Steroid-refractory acute GVHD with cardiac involvement (myocarditis or pericarditis pattern) and hemodynamic compromise — add ruxolitinib per REACH-2 + escalate systemic GVHD therapy
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Post-HSCT cardiogenic shock — etiology-stratified support with nephrotoxin avoidance + sub-etiology-specific treatment + MDT-gated MCS bridge
axis: post_hsct_cs_phenotype
Selected axis "Post-HSCT cardiogenic shock — etiology-stratified support with nephrotoxin avoidance + sub-etiology-specific treatment + MDT-gated MCS bridge" by default fallback (first axis)
  • norepinephrine
    first line
    vasopressor_alpha
    0.05–0.5 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: post_hsct_with_sbp_lt_90, cs_scai_c_or_higher
    SOAP-II PMID 20200382 — NE first-line in CS
    rxcui 7512
  • dobutamine
    second line
    inotrope_beta1
    2.5 µg/kg/min cautious titration • IV • continuous
    triggers: low_cardiac_output_despite_NE, no_active_VT_or_VF
    DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in inflamed myocardium given arrhythmia risk
    rxcui 3616
  • methylprednisolone
    first line
    corticosteroid_systemic
    1000 mg IV daily × 3–5 days, then 1 mg/kg/d taper • IV • daily
    triggers: cyclophosphamide_hemorrhagic_myocarditis_suspected, gvhd_cardiac_involvement, fulminant_inflammatory_pattern_post_conditioning
    Goldberg JCO 1986 PMID 3528404 — high-dose corticosteroids cornerstone for cyclophosphamide hemorrhagic myocarditis; AHA 2022 cardio-oncology + ESC 2022 (Lyon PMID 36017575)
    rxcui 6902
  • ganciclovir
    first line
    antiviral_dna_polymerase_inhibitor
    5 mg/kg IV q12h induction × 14–21 d (renal-adjust); maintenance 5 mg/kg IV daily • IV • q12h induction
    triggers: cmv_pcr_positive_with_cardiac_dysfunction, cmv_myocarditis_pcr_or_emb_confirmed
    ASTCT CMV management guideline (PMID 20530287) — IV ganciclovir is first-line for CMV end-organ disease post-HSCT including myocarditis; renal dose adjustment essential
    rxcui 4678
  • foscarnet
    second line
    antiviral_pyrophosphate_analog
    60 mg/kg IV q8h × 14–21 d (renal-adjust) • IV • q8h
    triggers: ganciclovir_resistant_cmv, severe_cytopenia_on_ganciclovir
    ASTCT CMV management — ganciclovir-resistant CMV; alternative if cytopenia limits ganciclovir; nephrotoxic — monitor closely
    rxcui 33562
  • immune globulin (IVIG)
    add on
    immune_globulin_polyclonal
    500 mg/kg IV q48h × 5 doses (CMV myocarditis adjunct) • IV • q48h
    triggers: cmv_myocarditis_confirmed_with_severe_dysfunction, severe_immunosuppression_with_viral_myocarditis
    ASTCT CMV management — IVIG adjunct in severe CMV pneumonitis / myocarditis post-HSCT; may also be considered for hypogammaglobulinemia + viral myocarditis context
    rxcui 1426680
  • ruxolitinib
    add on
    jak_inhibitor
    10 mg PO BID; titrate per platelet + ANC • PO • BID
    triggers: steroid_refractory_acute_gvhd_with_cardiac_involvement
    REACH-2 NEJM 2020 — ruxolitinib for steroid-refractory acute GVHD; relevant when GVHD-related cardiac involvement contributes to CS
    rxcui 1193325
  • amiodarone
    rescue
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min • IV • continuous
    triggers: ventricular_electrical_storm_in_inflamed_myocardium, sustained_vt_or_vf
    AHA 2020 ACLS Class IIb for refractory VT/VF
    rxcui 703
  • cefepime
    first line
    cephalosporin_4th_gen
    2 g IV q8h (renal-adjust) • IV • q8h
    triggers: neutropenic_fever_post_hsct, sepsis_with_hemodynamic_instability_post_hsct
    IDSA neutropenic fever 2010 + ASTCT supportive-care guidelines — empirical broad-spectrum β-lactam for febrile neutropenia in HSCT recipient
    rxcui 20481
  • AVOID nephrotoxic drugs
    contraindication substitute
    safety_marker
    AVOID aminoglycosides, NSAIDs, contrast unless essential; minimize loop diuretics if AKI; use nephrology-stewardship lens • n/a • n/a
    triggers: post_hsct_on_calcineurin_inhibitor, baseline_aki
    Calcineurin inhibitors (cyclosporine / tacrolimus) on board for GVHD prophylaxis cause AKI; avoid stacking nephrotoxins per ASTCT supportive-care guidance

outpatient playbook — drug actions (3)

  1. 1. continue or up-titrate GDMT 4-pillar if persistent EF<40
    sac/val + carvedilol + MRA + SGLT2i • PO • daily/BID
    trigger: Persistent EF<40
    AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499)
  2. 2. continue chronic immunosuppression per transplant team
    cyclosporine / tacrolimus per trough • PO • daily
    trigger: Chronic GVHD or maintenance per protocol
    EBMT chronic GVHD management; Tichelli 2008 PMID 18176622
  3. 3. AVOID re-exposure to high-dose anthracycline or cyclophosphamide if recovery achieved
    oncology + cardio-onc joint decision • n/a • n/a
    trigger: History of cyclophosphamide cardiotoxicity
    Lyon ESC 2022 cardio-onc (PMID 36017575) — re-exposure decision is risk-benefit with oncology

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recent high-dose cyclophosphamide conditioning (≥120 mg/kg) within past 1–10 d + acute HF + ↑ troponin → cyclophosphamide hemorrhagic myocarditis (Goldberg JCO 1986 PMID 3528404); HSCT recipient (allogeneic or autologous) within past 100 d + acute biventricular dysfunction + shock physiology — multi-etiology CS workup; CMV PCR positive + acute LV dysfunction in post-HSCT recipient (peak 30-100 d) → CMV myocarditis differential.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — post-hematopoietic-stem-cell-transplant recipient** (cardio.cardiogenic-shock.post-stem-cell-transplant.v1).
Scope: Confirm post-HSCT context; establish day-post-transplant + conditioning regimen + GVHD prophylaxis; identify suspected sub-etiology (cyclophosphamide hemorrhagic myocarditis vs CMV myocarditis vs sepsis-induced vs GVHD cardiac vs busulfan / TBI late effect)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Post-HSCT cardiogenic shock — etiology-stratified support with nephrotoxin avoidance + sub-etiology-specific treatment + MDT-gated MCS bridge**.
1. norepinephrine 0.05–0.5 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS
2. dobutamine 2.5 µg/kg/min cautious titration IV continuous (inotrope_beta1, second line) — DOREMI PMID 33704937 — non-inferior to milrinone; CAUTION in inflamed myocardium given arrhythmia risk
3. methylprednisolone 1000 mg IV daily × 3–5 days, then 1 mg/kg/d taper IV daily (corticosteroid_systemic, first line) — Goldberg JCO 1986 PMID 3528404 — high-dose corticosteroids cornerstone for cyclophosphamide hemorrhagic myocarditis; AHA 2022 cardio-oncology + ESC 2022 (Lyon PMID 36017575)
4. ganciclovir 5 mg/kg IV q12h induction × 14–21 d (renal-adjust); maintenance 5 mg/kg IV daily IV q12h induction (antiviral_dna_polymerase_inhibitor, first line) — ASTCT CMV management guideline (PMID 20530287) — IV ganciclovir is first-line for CMV end-organ disease post-HSCT including myocarditis; renal dose adjustment essential
5. foscarnet 60 mg/kg IV q8h × 14–21 d (renal-adjust) IV q8h (antiviral_pyrophosphate_analog, second line) — ASTCT CMV management — ganciclovir-resistant CMV; alternative if cytopenia limits ganciclovir; nephrotoxic — monitor closely
6. immune globulin (IVIG) 500 mg/kg IV q48h × 5 doses (CMV myocarditis adjunct) IV q48h (immune_globulin_polyclonal, add on) — ASTCT CMV management — IVIG adjunct in severe CMV pneumonitis / myocarditis post-HSCT; may also be considered for hypogammaglobulinemia + viral myocarditis context
7. ruxolitinib 10 mg PO BID; titrate per platelet + ANC PO BID (jak_inhibitor, add on) — REACH-2 NEJM 2020 — ruxolitinib for steroid-refractory acute GVHD; relevant when GVHD-related cardiac involvement contributes to CS
8. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min IV continuous (class_iii_antiarrhythmic, rescue) — AHA 2020 ACLS Class IIb for refractory VT/VF
9. cefepime 2 g IV q8h (renal-adjust) IV q8h (cephalosporin_4th_gen, first line) — IDSA neutropenic fever 2010 + ASTCT supportive-care guidelines — empirical broad-spectrum β-lactam for febrile neutropenia in HSCT recipient
10. AVOID nephrotoxic drugs AVOID aminoglycosides, NSAIDs, contrast unless essential; minimize loop diuretics if AKI; use nephrology-stewardship lens n/a n/a (safety_marker, contraindication substitute) — Calcineurin inhibitors (cyclosporine / tacrolimus) on board for GVHD prophylaxis cause AKI; avoid stacking nephrotoxins per ASTCT supportive-care guidance

Setting playbook (outpatient) — 4–8 wk recovery echo + CMR — confirm LV recovery; long-term GDMT if persistent HFrEF; long-term cardio-oncology surveillance for late TBI / busulfan / anthracycline effects; coordinate chronic GVHD + immunosuppression with transplant team; cancer-prognosis-weighted ICD eligibility per AHA 2017 VA/SCD
11. continue or up-titrate GDMT 4-pillar if persistent EF<40 sac/val + carvedilol + MRA + SGLT2i PO daily/BID — Persistent EF<40 (AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499))
12. continue chronic immunosuppression per transplant team cyclosporine / tacrolimus per trough PO daily — Chronic GVHD or maintenance per protocol (EBMT chronic GVHD management; Tichelli 2008 PMID 18176622)
13. AVOID re-exposure to high-dose anthracycline or cyclophosphamide if recovery achieved oncology + cardio-onc joint decision n/a n/a — History of cyclophosphamide cardiotoxicity (Lyon ESC 2022 cardio-onc (PMID 36017575) — re-exposure decision is risk-benefit with oncology)

Non-pharmacologic actions:
- No competitive sports for 3-6 mo per AHA / ESC sports cardiology
- Cardiac rehab if persistent LV dysfunction
- EP referral for ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting
- Transplant evaluation if persistent severe LV dysfunction + cancer-prognosis permits
- Long-term cardio-oncology surveillance (annual echo + GLS + CV risk assessment)

AVOID / contraindication checks:
- Nsaids_AVOID_in_post_hsct_with_calcineurin_inhibitor (additive nephrotoxicity)
- Aminoglycosides_AVOID_in_post_hsct (nephrotoxicity + ototoxicity stacking)
- Gadolinium_caution_if_egfr_lt_30 (NSF risk; group II macrocyclic agents safer)
- Ganciclovir_renal_adjust_required (renal clearance; cytopenia risk)
- Foscarnet_nephrotoxic_with_calcineurin_inhibitor_stacking (close monitoring)
- Contrast_minimize_in_post_hsct_with_aki (use ultrasound / CMR alternatives where feasible)
- High_dose_dobutamine_minimize_in_inflamed_myocardium (arrhythmia risk; escalate to MCS instead)
- Digoxin_AVOID_in_acute_myocarditis (toxicity threshold lowered in inflamed myocardium per ESC 2013)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q24h for recovery trajectory
- continuous telemetry for arrhythmia
- daily troponin and bnp
- daily cbc with diff for engraftment and anc
- calcineurin inhibitor trough q24-48h
- cmv pcr weekly
- ganciclovir renal adjusted dosing recheck with egfr
- liver panel daily for sos vod screen

Setting (outpatient) monitoring:
- Echo at 6 mo and 12 mo, then annually
- CMR at 6 mo if persistent LGE / hemorrhagic signal
- Calcineurin inhibitor trough monthly
- CMV PCR per ASTCT schedule

Follow-up plan: Repeat echo + CMR at 4-8 wks for recovery trajectory; cardiac rehab; long-term GDMT 4-pillar if persistent HFrEF; long-term cardio-oncology surveillance for late TBI / busulfan effects; coordination with transplant team for chronic GVHD + immunosuppression management; ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting
- Close-out criterion: Recovery echo + CMR + GDMT + ICD eligibility timeline + cardio-onc surveillance booked

Monitoring phase: A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q24h for LV recovery; daily troponin + BNP; daily CBC w/ diff; calcineurin inhibitor levels q24-48h; CMV PCR weekly; cultures pending

Disposition

Current setting: outpatient — 4–8 wk recovery echo + CMR — confirm LV recovery; long-term GDMT if persistent HFrEF; long-term cardio-oncology surveillance for late TBI / busulfan / anthracycline effects; coordinate chronic GVHD + immunosuppression with transplant team; cancer-prognosis-weighted ICD eligibility per AHA 2017 VA/SCD

Disposition criteria:
- Complete recovery (EF ≥55 + symptom-free + CMR resolved) → routine cardio-oncology surveillance
- Persistent HFrEF → long-term cross-link to cardio.hfref.core.v1 / cardio.hf.core.v1 with cardio-onc co-management

Escalation triggers (move to higher acuity):
- Sustained VT / syncope → EP urgent consult
- Persistent severe LV dysfunction → transplant evaluation if cancer-prognosis permits
- CMV reactivation → ID urgent consult
- Recurrent / new GVHD → transplant team

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Refractory CS within 1–10 d of high-dose cyclophosphamide (≥120 mg/kg) conditioning with hemorrhagic CMR pattern (T2*/SWI signal) — high-mortality variant (Goldberg JCO 1986); demands pulse steroids + supportive + MCS bridge with MDT
- [LIFE_THREATENING] CMV PCR positive (whole blood) + cardiac dysfunction in post-allogeneic HSCT recipient (peak 30–100 d post-transplant) — emergent ganciclovir + IVIG + ID consult; consider EMB
- [LIFE_THREATENING] Sepsis physiology + cardiac dysfunction in profoundly neutropenic post-HSCT recipient (ANC <500) — mortality very high; SSC 2026 sepsis bundle + broad-spectrum + antifungal + G-CSF + early MCS evaluation with MDT

Citations

- Lyon et al ESC 2022 cardio-oncology guideline (PMID 36017575); AHA 2022 cardio-oncology scientific statement; Yeh & Bickford JACC 2009 cardiotoxicity in HSCT (PMID 19608050); Tichelli EBMT 2008 cardiac complications HSCT (PMID 18176622); ASTCT CMV management (PMID 20530287); REACH-2 NEJM 2020 (ruxolitinib for steroid-refractory acute GVHD) [PMID:19608050](https://pubmed.ncbi.nlm.nih.gov/19608050/)
- Cited evidence (PMID 18176622) [PMID:18176622](https://pubmed.ncbi.nlm.nih.gov/18176622/)
- Cited evidence (PMID 3528404) [PMID:3528404](https://pubmed.ncbi.nlm.nih.gov/3528404/)
- Cited evidence (PMID 36017575) [PMID:36017575](https://pubmed.ncbi.nlm.nih.gov/36017575/)
- Cited evidence (PMID 20530287) [PMID:20530287](https://pubmed.ncbi.nlm.nih.gov/20530287/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Lyon et al ESC 2022 cardio-oncology guideline (PMID 36017575); AHA 2022 cardio-oncology scientific statement; Yeh & Bickford JACC 2009 cardiotoxicity in HSCT (PMID 19608050); Tichelli EBMT 2008 cardiac complications HSCT (PMID 18176622); ASTCT CMV management (PMID 20530287); REACH-2 NEJM 2020 (ruxolitinib for steroid-refractory acute GVHD) — PMID:19608050
  • Cited evidence (PMID 18176622) — PMID:18176622
  • Cited evidence (PMID 3528404) — PMID:3528404
  • Cited evidence (PMID 36017575) — PMID:36017575
  • Cited evidence (PMID 20530287) — PMID:20530287